A 48-month, multicenter, observational study to evaluate the long-term efficacy of Elocta in joint health.
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: SWEDISH ORPHAN BIOVITRUM AB
- Execution start: 08/09/2020
- End of execution: 30/12/2025
- IP: